search
Back to results

The Effect of Exercise on Serum Levels of Collagen and Proteoglycan in Patients With Knee Osteoarthritis (EFEX-OA-02)

Primary Purpose

Osteoarthritis, Knee

Status
Completed
Phase
Not Applicable
Locations
Denmark
Study Type
Interventional
Intervention
Cycling then running
Running then cycling
Inotropy
Resting
Sponsored by
Nordic Bioscience A/S
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional basic science trial for Osteoarthritis, Knee

Eligibility Criteria

40 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Cumulated Osteoarthritis Kellgren-Lawrence radiological grade of at least 2 in the tibio-femoral joints diagnosed by screening X-ray.
  2. 40 to < 75 years of age at time of signing the informed consent.
  3. Body weight > 50 and < 100 kg and BMI in the range 18.5-35 kg/m2 .
  4. Male or female.
  5. Able to attend all four study sessions and comply with the dietary and activity restrictions.
  6. Able to provide informed consent

Exclusion Criteria:

Medical conditions:

  1. Osteoarthritis Kellgren-Lawrence radiological grade of 4 in one or both knees.
  2. Cumulated osteoarthritis Kellgren-Lawrence radiological grade no higher than 1.
  3. History of arthroscopy or intra-articular administration of corticosteroids or hyaluronic acid into the target knee within 6 months before screening.
  4. Previous arthroplasty of knee or hip.
  5. Intention to have major surgery during the timeframe of the study.
  6. Secondary OA related to e.g. any known trauma including cruciate ligament tears, meniscus tears and cartilage damage, dysplasia, aseptic osteonecrosis, acromegaly, Paget disease, Stickler syndrome, hemochromatosis, gout, chondrocalcinosis (pseudogout).
  7. Current treatment with beta-receptor adrenergic antagonists (beta-blockers), MAO inhibitor, systemic corticosteroid treatment in doses equivalent to > 10 mg prednisolone per day, or vitamin K antagonists, new oral anticoagulants, fractionated and non-fractionated heparin.
  8. Active systemic infection.
  9. Active systemic inflammatory or autoimmune disease.
  10. Any sign of previous or current cardiovascular disease.
  11. Not currently an active athlete or highly trained individual.

Other exclusion criteria:

  1. Legal incapacity or limited legal capacity.
  2. Inability to communicate or cooperate with the investigator or to comply with the requirements of the entire study.
  3. Categorized as being very difficult to draw blood from, as evaluated by the investigator.
  4. Current alcohol abuse and/or inability to refrain from intake of alcoholic beverages for 24 hours prior to the study intervention.
  5. Other factors, e.g. self-reported drug abuse, which in the opinion of the investigator may interfere with the performance of the study.
  6. Site staff, study staff members and study staff family members.
  7. Other concomitant disease compromising or otherwise significantly affecting ECM turnover in the opinion of the investigator.

Sites / Locations

  • Rigshospitalet

Arms of the Study

Arm 1

Arm 2

Arm Type

Other

Other

Arm Label

Cycling as first intervention

Running as first intervention

Arm Description

Cycling -> Running -> Inotropy -> Resting

Running -> Cycling -> Inotropy -> Resting

Outcomes

Primary Outcome Measures

Acute chances in biomarkers
Serum and urine biochemical markers of joint related collagens and proteoglycan (not further specified)

Secondary Outcome Measures

Full Information

First Posted
August 27, 2020
Last Updated
June 7, 2021
Sponsor
Nordic Bioscience A/S
Collaborators
University of Copenhagen, NBCD A/S
search

1. Study Identification

Unique Protocol Identification Number
NCT04542668
Brief Title
The Effect of Exercise on Serum Levels of Collagen and Proteoglycan in Patients With Knee Osteoarthritis
Acronym
EFEX-OA-02
Official Title
An Open-label, Randomized, Cross-over Study to Investigate the Effect of Weight-bearing vs Non-weight-bearing Exercise and Cardiovascular Stress Without Load on Collagen and Proteoglycan in Serum and Urine in Patients With Osteoarthritis
Study Type
Interventional

2. Study Status

Record Verification Date
June 2021
Overall Recruitment Status
Completed
Study Start Date
October 8, 2020 (Actual)
Primary Completion Date
June 7, 2021 (Actual)
Study Completion Date
June 7, 2021 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Nordic Bioscience A/S
Collaborators
University of Copenhagen, NBCD A/S

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The aim of EFEX-OA-02 is to explore how running, cycling, exercise simulation and resting acutely influence collagen and proteoglycan homeostasis in OA, as reflected by changes in collagen and proteoglycan levels in urine and serum.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Osteoarthritis, Knee

7. Study Design

Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Model Description
The study period will be 4 weeks. In each week, the subjects will undergo a different physical activity intervention. The order of the interventions will be randomized. The interventions will be separated by a minimum of 4 days. Inteventions: Cycling, Running, exercise-simulation with inotropy and resting.
Masking
None (Open Label)
Allocation
Randomized
Enrollment
40 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Cycling as first intervention
Arm Type
Other
Arm Description
Cycling -> Running -> Inotropy -> Resting
Arm Title
Running as first intervention
Arm Type
Other
Arm Description
Running -> Cycling -> Inotropy -> Resting
Intervention Type
Other
Intervention Name(s)
Cycling then running
Other Intervention Name(s)
Exercise
Intervention Description
Ergometer cycling Treadmill running
Intervention Type
Other
Intervention Name(s)
Running then cycling
Other Intervention Name(s)
Exercise
Intervention Description
Treadmill running Ergometer cycling
Intervention Type
Other
Intervention Name(s)
Inotropy
Other Intervention Name(s)
Exercise simulation
Intervention Description
Adrenaline induced inotropy
Intervention Type
Other
Intervention Name(s)
Resting
Other Intervention Name(s)
Non-Ex
Intervention Description
Subjects must be minimally physically active
Primary Outcome Measure Information:
Title
Acute chances in biomarkers
Description
Serum and urine biochemical markers of joint related collagens and proteoglycan (not further specified)
Time Frame
Acute: 0-4 hours and subacute: 24 hours

10. Eligibility

Sex
All
Minimum Age & Unit of Time
40 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Cumulated Osteoarthritis Kellgren-Lawrence radiological grade of at least 2 in the tibio-femoral joints diagnosed by screening X-ray. 40 to < 75 years of age at time of signing the informed consent. Body weight > 50 and < 100 kg and BMI in the range 18.5-35 kg/m2 . Male or female. Able to attend all four study sessions and comply with the dietary and activity restrictions. Able to provide informed consent Exclusion Criteria: Medical conditions: Osteoarthritis Kellgren-Lawrence radiological grade of 4 in one or both knees. Cumulated osteoarthritis Kellgren-Lawrence radiological grade no higher than 1. History of arthroscopy or intra-articular administration of corticosteroids or hyaluronic acid into the target knee within 6 months before screening. Previous arthroplasty of knee or hip. Intention to have major surgery during the timeframe of the study. Secondary OA related to e.g. any known trauma including cruciate ligament tears, meniscus tears and cartilage damage, dysplasia, aseptic osteonecrosis, acromegaly, Paget disease, Stickler syndrome, hemochromatosis, gout, chondrocalcinosis (pseudogout). Current treatment with beta-receptor adrenergic antagonists (beta-blockers), MAO inhibitor, systemic corticosteroid treatment in doses equivalent to > 10 mg prednisolone per day, or vitamin K antagonists, new oral anticoagulants, fractionated and non-fractionated heparin. Active systemic infection. Active systemic inflammatory or autoimmune disease. Any sign of previous or current cardiovascular disease. Not currently an active athlete or highly trained individual. Other exclusion criteria: Legal incapacity or limited legal capacity. Inability to communicate or cooperate with the investigator or to comply with the requirements of the entire study. Categorized as being very difficult to draw blood from, as evaluated by the investigator. Current alcohol abuse and/or inability to refrain from intake of alcoholic beverages for 24 hours prior to the study intervention. Other factors, e.g. self-reported drug abuse, which in the opinion of the investigator may interfere with the performance of the study. Site staff, study staff members and study staff family members. Other concomitant disease compromising or otherwise significantly affecting ECM turnover in the opinion of the investigator.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Niels Secher, MD, DMSci
Organizational Affiliation
University of Copenhagen
Official's Role
Principal Investigator
Facility Information:
Facility Name
Rigshospitalet
City
Copenhagen
ZIP/Postal Code
2100
Country
Denmark

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

The Effect of Exercise on Serum Levels of Collagen and Proteoglycan in Patients With Knee Osteoarthritis

We'll reach out to this number within 24 hrs